Published in Cell Death Differ on June 07, 2013
Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol (2014) 4.28
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ (2014) 2.66
RIP3: a molecular switch for necrosis and inflammation. Genes Dev (2013) 1.94
Autosis and autophagic cell death: the dark side of autophagy. Cell Death Differ (2014) 1.49
Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer (2015) 1.39
Die another way--non-apoptotic mechanisms of cell death. J Cell Sci (2014) 1.27
Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol (2014) 1.13
Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. Oncogene (2015) 1.11
Recent insights into cell death and autophagy. FEBS J (2015) 1.08
The Autophagy Machinery Controls Cell Death Switching between Apoptosis and Necroptosis. Dev Cell (2016) 1.02
Disrupted autophagy after spinal cord injury is associated with ER stress and neuronal cell death. Cell Death Dis (2015) 1.01
The mechanism of necroptosis in normal and cancer cells. Cancer Biol Ther (2013) 0.93
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol (2015) 0.92
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol (2013) 0.91
Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis (2015) 0.89
Sorafenib-induced defective autophagy promotes cell death by necroptosis. Oncotarget (2015) 0.89
Function and Mechanisms of Autophagy in Brain and Spinal Cord Trauma. Antioxid Redox Signal (2015) 0.88
An outline of necrosome triggers. Cell Mol Life Sci (2016) 0.86
Current questions and possible controversies in autophagy. Cell Death Discov (2015) 0.86
OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. PLoS One (2013) 0.83
Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells. Oncotarget (2016) 0.83
Necroptosis: an alternative cell death program defending against cancer. Biochim Biophys Acta (2016) 0.82
Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression. Endocr Relat Cancer (2014) 0.82
Cancer therapy in the necroptosis era. Cell Death Differ (2016) 0.81
Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy (2016) 0.81
Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells. J Exp Clin Cancer Res (2015) 0.80
High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting. Mol Cancer Res (2014) 0.80
SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. Oncotarget (2016) 0.80
Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. BMC Cancer (2015) 0.79
Sparse expression bases in cancer reveal tumor drivers. Nucleic Acids Res (2015) 0.79
Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. Oncotarget (2016) 0.78
Relevance of necroptosis in cancer. Immunol Cell Biol (2016) 0.78
The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization. PLoS One (2016) 0.78
Necroptotic cell death in failing heart: relevance and proposed mechanisms. Heart Fail Rev (2016) 0.78
Autophagic cell death RIPs into tumors. Cell Death Differ (2013) 0.77
Deficiency in the mitochondrial apoptotic pathway reveals the toxic potential of autophagy under ER stress conditions. Autophagy (2014) 0.77
Cell Death Conversion under Hypoxic Condition in Tumor Development and Therapy. Int J Mol Sci (2015) 0.77
Key roles of necroptotic factors in promoting tumor growth. Oncotarget (2016) 0.77
Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis. Oncotarget (2016) 0.77
Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia. Am J Cancer Res (2015) 0.76
The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy. Front Oncol (2015) 0.76
Impaired Autophagy and Defective Mitochondrial Function: Converging Paths on the Road to Motor Neuron Degeneration. Front Cell Neurosci (2016) 0.76
Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells. Mol Cell Biol (2016) 0.75
Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. Cell Death Dis (2017) 0.75
Comparison of in vitro antileukemic activity of obatoclax and ABT-737. Tumour Biol (2016) 0.75
Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer (2016) 0.75
Natural Compounds As Modulators of Non-apoptotic Cell Death in Cancer Cells. Curr Genomics (2017) 0.75
Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells. Int J Mol Sci (2016) 0.75
Keeping autophagy in cheCK1. Mol Cell Oncol (2015) 0.75
Autophagy in Cancer Therapy. Front Oncol (2017) 0.75
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer. Int J Mol Sci (2017) 0.75
Targeting autophagy in cancer. Nat Rev Cancer (2017) 0.75
BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells. Oncotarget (2016) 0.75
Atg2A/B deficiency switches cytoprotective autophagy to non-canonical caspase-8 activation and apoptosis. Cell Death Differ (2017) 0.75
Exploitation of necroptosis for treatment of caspase-compromised cancers. Oncol Lett (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol (2005) 11.63
Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell (2009) 11.36
Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science (2004) 10.77
The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 10.08
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol (2009) 9.32
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol (2011) 8.18
Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell (2008) 7.61
Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell (2009) 5.55
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J Biol Chem (2005) 4.56
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07
The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal (2010) 3.20
Rhabdomyosarcoma: an overview. Oncologist (1999) 2.68
FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc Natl Acad Sci U S A (2008) 2.52
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther (2009) 2.21
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
Rhabdomyosarcoma--working out the pathways. Oncogene (1999) 2.12
Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest (2010) 1.97
Autophagy and apoptosis: what is the connection? Trends Cell Biol (2011) 1.81
Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. J Biol Chem (2012) 1.79
Autophagy plays a protective role during zVAD-induced necrotic cell death. Autophagy (2008) 1.77
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 1.77
The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res (1997) 1.76
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol (2009) 1.38
Inhibition of protein degradation induces apoptosis through a microtubule-associated protein 1 light chain 3-mediated activation of caspase-8 at intracellular membranes. Mol Cell Biol (2011) 1.29
Activation of the PI3K-Akt-mTOR signaling pathway promotes necrotic cell death via suppression of autophagy. Autophagy (2009) 1.29
Cell death in health and disease. J Cell Mol Med (2007) 1.27
Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis (2010) 1.23
Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene (2000) 1.22
GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis (2010) 1.17
Rhabdomyosarcoma in children. Curr Opin Pediatr (2009) 1.17
RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia (2011) 1.15
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene (2009) 1.12
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res (2010) 1.08
Autophagy is a survival force via suppression of necrotic cell death. Exp Cell Res (2012) 1.07
The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett (2010) 1.02
Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes. Histol Histopathol (2009) 0.93
Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells. Int J Oncol (2011) 0.92
Receptor proteins in selective autophagy. Int J Cell Biol (2012) 0.87
Autophagy and cell death. Autophagy (2012) 0.87
Cell death pathways as therapeutic targets in rhabdomyosarcoma. Sarcoma (2012) 0.82
The autophagosome is overrated! Autophagy (2011) 0.82
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ (2010) 2.26
CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut (2010) 1.63
Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood (2001) 1.51
Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene (2006) 1.42
Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene (2006) 1.37
Cytotoxic drugs and the CD95 pathway. Leukemia (1999) 1.30
Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis. FASEB J (2005) 1.27
Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci U S A (1999) 1.25
PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene (2010) 1.24
Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia (1997) 1.19
Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene (2010) 1.17
Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. Cell Death Differ (2012) 1.17
Pleiotropic effects of sonic hedgehog on muscle satellite cells. Cell Mol Life Sci (2005) 1.15
RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia (2011) 1.15
RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex. Oncogene (2012) 1.12
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene (2009) 1.12
Depression, comorbidities and the TNF-alpha system. Eur Psychiatry (2008) 1.12
Betulinic acid-induced apoptosis in leukemia cells. Leukemia (2004) 1.09
Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. Oncogene (2012) 1.09
Daytime variation in performance and tiredness/sleepiness ratings in patients with insomnia, narcolepsy, sleep apnea and normal controls. J Sleep Res (2004) 1.09
Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood (1997) 1.08
Restless legs syndrome in the emergency room. Eur J Neurol (2013) 1.07
Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ (1999) 1.06
Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Cell Death Dis (2013) 1.05
Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene (2007) 1.04
Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis (2013) 1.04
Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Curr Med Chem (2012) 1.00
The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene (2009) 0.99
Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene (2012) 0.99
Identification of a novel pro-apoptotic role of NF-κB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells. Oncogene (2011) 0.99
Identification of DR5 as a critical, NF-κB-regulated mediator of Smac-induced apoptosis. Cell Death Dis (2013) 0.98
Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene (2008) 0.98
Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Cancer (2000) 0.97
MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene (1998) 0.95
ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis (2012) 0.93
Thirty-eight-negative kinase 1 (TNK1) facilitates TNFalpha-induced apoptosis by blocking NF-kappaB activation. Oncogene (2007) 0.93
Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene (2007) 0.93
Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation. Cell Death Dis (2013) 0.92
NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. Oncogene (2006) 0.91
Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis. Cancer Res (2000) 0.91
The role of survivin for radiation oncology: moving beyond apoptosis inhibition. Curr Med Chem (2011) 0.91
Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia (2011) 0.90
4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ (2007) 0.89
NOXA as critical mediator for drug combinations in polychemotherapy. Cell Death Dis (2012) 0.88
An introduction to molecular targeted therapy of cancer. Adv Med Sci (2008) 0.88
Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction. Biochem Soc Trans (1997) 0.86
Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene (2011) 0.82
Role of Smac in cephalostatin-induced cell death. Cell Death Differ (2008) 0.82
Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity. Leukemia (1999) 0.80
Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses. Leukemia (2011) 0.78
Prevalence of the restless legs syndrome in transsexual patients: the hormonal hypothesis revisited. J Neurol (2007) 0.78
Impact of daytime sleepiness on rehabilitation outcome in the elderly. Adv Exp Med Biol (2013) 0.77
Validation of the Essener Questionnaire of Age and Sleepiness in the elderly using pupillometry. Adv Exp Med Biol (2013) 0.77
Effect of gravity changes on the cyanobacterium Synechocystis sp. PCC 6803. Curr Microbiol (1997) 0.76
The dark side of TRAIL signaling. Cell Death Differ (2013) 0.76
First EACR Conference on Cell Death in Cancer, Amsterdam, Netherlands, 26-28 January 2012. Cell Death Differ (2012) 0.75
Hypersomnia due to bilateral thalamic lesions: unexpected response to Modafinil. Eur J Neurol (2012) 0.75
Novel job opportunities in cell death! Biochem Pharmacol (2008) 0.75